Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What are Second Messengers?01:12

What are Second Messengers?

Because many receptor binding ligands are hydrophilic, they do not cross the cell membrane and thus their message must be relayed to a second messenger on the inside. There are several second messenger pathways, each with their own way of relaying information. G-protein coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol path is active when the receptor induces phospholipase C to hydrolyze the phospholipid,...
What are Second Messengers?01:12

What are Second Messengers?

Because many receptor binding ligands are hydrophilic, they do not cross the cell membrane and thus their message must be relayed to a second messenger on the inside. There are several second messenger pathways, each with their own way of relaying information. G-protein coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol path is active when the receptor induces phospholipase C to hydrolyze the phospholipid,...
Amplifying Signals via Second Messengers01:15

Amplifying Signals via Second Messengers

Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of chronic subdural hematoma: a consensus statement from the 2024 Copenhagen joint iCORIC/DACSUHS symposium.

Acta neurochirurgica·2026
Same author

Updated systematic review of current randomised controlled trials in chronic subdural haematoma.

Acta neurochirurgica·2025
Same author

Multidisciplinary consensus-based statement on the current role of middle meningeal artery embolization (MMAE) in chronic SubDural hematoma (cSDH).

Brain & spine·2024
Same author

Expertise in surgical neuro-oncology. Results of a survey by the EANS neuro-oncology section.

Brain & spine·2024
Same author

Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.

BMC cancer·2022
Same author

Return to work following meningioma surgery: a Swedish nationwide registry-based matched cohort study.

Neuro-oncology practice·2020
Same journal

Human aminoacyl-tRNA synthetases as integrators of translation and cell signalling networks.

Nature reviews. Molecular cell biology·2026
Same journal

How proteins fold.

Nature reviews. Molecular cell biology·2026
Same journal

Single-cell evidence for PANoptosome complexes.

Nature reviews. Molecular cell biology·2026
Same journal

Reply to 'Single-cell evidence for PANoptosome complexes'.

Nature reviews. Molecular cell biology·2026
Same journal

Plucking cellular ribosomes with Ribo-Tweezer.

Nature reviews. Molecular cell biology·2026
Same journal

COPII meets autophagy at the ER membrane.

Nature reviews. Molecular cell biology·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

CHK2 kinase--a busy messenger.

J Bartek1, J Falck, J Lukas

  • 1Danish Cancer Society, Institute of Cancer Biology, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark. bartek@biobase.dk

Nature Reviews. Molecular Cell Biology
|December 6, 2001
PubMed
Summary
This summary is machine-generated.

Checkpoint kinase 2 (Chk2) is crucial for genome integrity and DNA repair. Its dysfunction is linked to cancer, making Chk2 a potential drug target for cancer therapy.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Genetics

Background:

  • Checkpoint kinase 2 (Chk2) plays a vital role in cellular responses to DNA damage.
  • Chk2 is a key component of genome surveillance pathways essential for maintaining genomic stability.
  • Its function is conserved across eukaryotic evolution.

Purpose of the Study:

  • To elucidate the fundamental role of Chk2 in genome surveillance pathways.
  • To highlight Chk2's involvement in coordinating cell-cycle progression, DNA repair, and cell fate.
  • To underscore Chk2's significance as a potential tumor suppressor and drug discovery target.

Main Methods:

  • Review of recent studies on Chk2 function.
  • Analysis of Chk2's role in DNA repair and cell-cycle checkpoints.
  • Investigation of Chk2's implications in cancer development.

Main Results:

  • Chk2 is confirmed as a central mediator of cellular responses to genotoxic stress.
  • Chk2 integrates DNA repair, cell-cycle control, and cell survival/death decisions.
  • Defects in Chk2 are associated with hereditary and sporadic human cancers.

Conclusions:

  • Chk2 is essential for guarding genome integrity.
  • Its role in DNA damage response pathways makes it a critical factor in preventing cancer.
  • Chk2 represents a promising target for novel cancer therapeutics.